| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $0 | 0 | 0 |
Sells | $324,234,165 | 5 | 100 |
| SANSONE GUY P | director | 1 | $100,009 | 0 | $0 | $100,009 |
| Finucane Anne A. | director | 0 | $0 | 1 | $532,650 | $-532,650 |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer | 0 | $0 | 1 | $6.23M | $-6.23M |
| ROBBINS LARRY | director | 0 | $0 | 3 | $317.47M | $-317.47M |
CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company's Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. As of December 31, 2021, it operated approximately 9,900 retail locations and 1,200 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Over the last 12 months, insiders at CVS Health Corporation have bought $0 and sold $324.23M worth of CVS Health Corporation stock.
On average, over the past 5 years, insiders at CVS Health Corporation have bought $1.09M and sold $132.46M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,570 shares for transaction amount of $100,009 was made by SANSONE GUY P (director) on 2025‑06‑05.
| 2026-05-21 | Sale | ROBBINS LARRY | director | 370,462 0.0291% | $93.45 | $34.62M | -2.28% | |
| 2026-05-20 | Sale | ROBBINS LARRY | director | 1.02M 0.0802% | $93.82 | $95.51M | -3.23% | |
| 2026-05-19 | Sale | ROBBINS LARRY | director | 1.98M 0.1559% | $94.45 | $187.34M | -2.32% | |
| 2026-05-08 | Sale | Mandadi Tilak | EVP, Chief Exp & Tech Officer | 69,551 0.0054% | $89.58 | $6.23M | +3.48% | |
| 2025-08-20 | Sale | Finucane Anne A. | director | 7,500 0.0006% | $71.02 | $532,650 | +11.44% | |
| 2025-06-05 | SANSONE GUY P | director | 1,570 0.0001% | $63.70 | $100,009 | +24.50% | ||
| 2025-05-06 | Sale | ROBBINS LARRY | director | 150,000 0.012% | $66.67 | $10M | +17.00% | |
| 2025-05-05 | Sale | ROBBINS LARRY | director | 1.32M 0.1054% | $67.41 | $89.25M | +15.48% | |
| 2025-05-02 | Sale | ROBBINS LARRY | director | 2.28M 0.1814% | $67.86 | $154.44M | +14.60% | |
| 2025-03-05 | Sale | Clark James David | SVP, Cont & Chief Acct Officer | 7,513 0.0006% | $66.35 | $498,488 | +13.34% | |
| 2025-02-18 | Mahoney Michael F | director | 30,000 0.0024% | $66.70 | $2M | +9.44% | ||
| 2025-01-23 | Nelson Steven H | EVP and President, Aetna | 24 <0.0001% | $53.70 | $1,289 | +26.87% | ||
| 2024-10-23 | CAPOZZI HEIDI B | EVP and Chief People Officer | 35 <0.0001% | $56.85 | $1,990 | +16.05% | ||
| 2024-10-02 | CAPOZZI HEIDI B | EVP and Chief People Officer | 10 <0.0001% | $62.24 | $622 | +6.08% | ||
| 2024-09-09 | CAPOZZI HEIDI B | EVP and Chief People Officer | 35 <0.0001% | $56.47 | $1,976 | +15.43% | ||
| 2024-05-02 | LUDWIG EDWARD J | director | 1,000 <0.0001% | $53.88 | $53,879 | +7.00% | ||
| 2024-05-02 | Mahoney Michael F | director | 9,181 0.0007% | $54.49 | $500,294 | +7.00% | ||
| 2024-02-16 | Sale | Shah Prem S | EVP and Pres-Pharm, Consumer W | 29,473 0.0023% | $76.95 | $2.27M | -22.74% | |
| 2023-11-03 | LUDWIG EDWARD J | director | 2,000 0.0002% | $70.47 | $140,930 | -4.47% | ||
| 2023-08-03 | Sale | Clark James David | SVP, Cont & Chief Acct Officer | 25,759.26 0.002% | $74.92 | $1.93M | -5.56% |
| ROBBINS LARRY | director | 4824799 0.3781% | $462.84M | 0 | 6 | |
| Finucane Anne A. | director | 22156 0.0017% | $2.13M | 0 | 4 | |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer | 10133 0.0008% | $972,058.69 | 0 | 1 | |
| RYAN THOMAS M | Non-Executive Chairman | 764683 0.0599% | $73.36M | 2 | 20 | +6.97% |
| GOLDSTEIN STANLEY P | director | 660206 0.0517% | $63.33M | 0 | 17 | |
| Moriarty Thomas M | EVP & General Counsel | 608129 0.0477% | $58.34M | 1 | 9 | +14.87% |
| MERLO LARRY J | director | 524026 0.0411% | $50.27M | 0 | 24 | |
| Lynch Karen S | President and CEO | 431392 0.0338% | $41.38M | 1 | 1 | +2.4% |
| HEADRICK ROGER L | director | 324262 0.0254% | $31.11M | 1 | 0 | +3.11% |
| RICKARD DAVID B | Chief Financial Officer | 207179 0.0162% | $19.87M | 0 | 3 | |
| PICCOLO C A | director | 181461 0.0142% | $17.41M | 0 | 2 | |
| Brennan Troyen A | EVP and Chief Medical Officer | 138246 0.0108% | $13.26M | 1 | 25 | |
| CRAWFORD EDWIN M | Chairman | 135498 0.0106% | $13M | 0 | 2 | |
| DORMAN DAVID W | director | 122302 0.0096% | $11.73M | 2 | 0 | +12.47% |
| Boratto Eva C | EVP & CFO | 115331 0.009% | $11.06M | 0 | 13 | |
| BROWN C DAVID II | director | 111252 0.0087% | $10.67M | 2 | 4 | +11.66% |
| Lotvin Alan | EVP&President-PharmacyServices | 109183 0.0086% | $10.47M | 1 | 5 | +6.03% |
| Roberts Jonathan C | EVP & Chief Operating Officer | 107115 0.0084% | $10.28M | 0 | 15 | |
| MURRAY TERRENCE | director | 80506 0.0063% | $7.72M | 4 | 3 | +6.18% |
| WILLIAMS KRISTEN GIBNEY | director | 64679 0.0051% | $6.2M | 1 | 3 | +7.56% |
| Bisaccia Lisa | EVP and Chief HR Officer | 46588 0.0037% | $4.47M | 0 | 13 | |
| COSBY MARK | EVP & President-CVS/pharmacy | 45955 0.0036% | $4.41M | 0 | 1 | |
| Joyner J. David | EVP, Sales & Account Services | 45399 0.0036% | $4.36M | 0 | 5 | |
| Foulkes Helena | EVP & President-CVS Pharmacy | 45107 0.0035% | $4.33M | 0 | 14 | |
| Mahoney Michael F | director | 39356 0.0031% | $3.78M | 2 | 0 | +8.22% |
| Shah Prem S | EVP and Pres-Pharm, Consumer W | 39765 0.0031% | $3.81M | 0 | 4 | |
| Finke Daniel P | EVP/Pres, Health Care Benefits | 32150 0.0025% | $3.08M | 0 | 3 | |
| GERRITY THOMAS P | director | 31165 0.0024% | $2.99M | 0 | 5 | |
| LAUTENBACH TERRY R | director | 27915 0.0022% | $2.68M | 0 | 1 | |
| Flum Joshua Matthew | EVP, ENT STRATEGY & DIGITAL | 25001 0.002% | $2.4M | 0 | 2 | |
| BANKS EDWIN M | director | 23187 0.0018% | $2.22M | 0 | 3 | |
| Lofberg Per GH | EVP | 23419 0.0018% | $2.25M | 5 | 3 | +6.91% |
| LUDWIG EDWARD J | director | 21630 0.0017% | $2.07M | 7 | 0 | +8.71% |
| GOLD STEPHEN J | EVP & CIO | 21560 0.0017% | $2.07M | 1 | 2 | +6.79% |
| FERDINANDI V MICHAEL | Senior Vice President | 16021 0.0013% | $1.54M | 1 | 5 | +36.25% |
| AGUIRRE FERNANDO | director | 16222 0.0013% | $1.56M | 2 | 0 | +11.6% |
| SANSONE GUY P | director | 12007 0.0009% | $1.15M | 1 | 0 | |
| MCGUIGAN STUART M | SVP and CIO | 10967 0.0009% | $1.05M | 1 | 3 | +14.86% |
| Finley Sara | SVP, Gen Counsel | 8525 0.0007% | $817,803.25 | 0 | 1 | |
| Sussman Andrew | EVP, Clinical Services | 8697 0.0007% | $834,303.21 | 0 | 8 | |
| Clark James David | SVP, Cont & Chief Acct Officer | 8394 0.0007% | $805,236.42 | 0 | 8 | |
| Mayhew Jonathan E. | EVP - Transformation | 4732 0.0004% | $453,940.76 | 0 | 1 | |
| WEISHAR GREGORY S | Vice President | 4010 0.0003% | $384,679.30 | 0 | 1 | |
| SWIFT RICHARD J | director | 3258 0.0003% | $312,539.94 | 1 | 1 | +34.77% |
| Hourican Kevin | EVP & President, CVS Pharmacy | 3571 0.0003% | $342,566.03 | 0 | 1 | |
| BODINE CHRIS W | Executive Vice President | 2583 0.0002% | $247,796.65 | 1 | 7 | +1.8% |
| MILLON JEAN PIERRE | director | 0 0% | $0 | 0 | 4 | |
| SGARRO DOUGLAS A | EVP and CLO | 214 0% | $20,547.20 | 0 | 13 | |
| SOLBERG LARRY D | Senior Vice President | 0 0% | $0 | 0 | 3 | |
| MCLURE HOWARD A | President, Caremark Pharm Serv | 0 0% | $0 | 0 | 7 | |
| VERRECCHIA ALFRED J | director | 0 0% | $0 | 0 | 1 | |
| Nelson Steven H | EVP and President, Aetna | 24 0% | $2,302.32 | 1 | 0 | +26.87% |
| Spalding William R | EVP Caremark Pharmacy Services | 182 0% | $17,459.26 | 0 | 1 | |
| Denton David M | EVP and CFO | 403 0% | $38,657.55 | 1 | 8 | |
| CAPOZZI HEIDI B | EVP and Chief People Officer | 85 0% | $8,154.05 | 3 | 0 | +12.52% |
| Increased Positions | 964 | +47.51% | 76M | +6.81% |
| Decreased Positions | 887 | -43.72% | 63M | -5.59% |
| New Positions | 251 | New | 14M | New |
| Sold Out Positions | 127 | Sold Out | 4M | Sold Out |
| Total Postitions | 2,106 | +3.79% | 1B | +1.22% |
| Blackrock, Inc. | $9.6M | 9.44% | 119.84M | -3M | -2.32% | 2025-09-30 |
| Vanguard Group Inc | $9.53M | 9.37% | 118.89M | -2M | -1.26% | 2025-09-30 |
| Dodge & Cox | $5.86M | 5.77% | 73.18M | -112,180 | -0.15% | 2025-09-30 |
| Capital World Investors | $5.48M | 5.39% | 68.38M | +1M | +2.12% | 2025-09-30 |
| State Street Corp | $4.72M | 4.64% | 58.94M | +149,701 | +0.26% | 2025-09-30 |
| Fmr Llc | $3.47M | 3.42% | 43.34M | -2M | -4.99% | 2025-09-30 |
| Jpmorgan Chase & Co | $2.83M | 2.78% | 35.28M | +8M | +31.25% | 2025-09-30 |
| Geode Capital Management, Llc | $2.32M | 2.28% | 28.99M | +352,532 | +1.23% | 2025-09-30 |
| Capital International Investors | $2.14M | 2.1% | 26.69M | +302,499 | +1.15% | 2025-09-30 |
| Invesco Ltd. | $1.95M | 1.91% | 24.29M | +760,579 | +3.23% | 2025-09-30 |